New Breakthrough: Just Two Annual Injections May Ease High Cholesterol, Fatty Liver and Kidney Diseases

Chronic lifestyle-related diseases such as high cholesterol, fatty liver and chronic kidney disorders have become increasingly common in India. Sedentary habits, poor dietary quality, rising sugar intake and obesity have significantly contributed to this growing health burden. However, recent breakthroughs in pharmaceutical research have brought promising solutions — including treatments that require as little as two injections per year

to manage some of these chronic conditions more effectively.

This new wave of therapy, driven by global innovators and supported by Indian pharmaceutical companies, is reshaping how these conditions are treated. Here’s a detailed look at the latest medical advancements.

1. High Cholesterol (Hyperlipidemia): Advanced PCSK9 Inhibitors Lead the Way

For decades, statins have been the primary option for lowering LDL or “bad” cholesterol. But a revolutionary class of medicines known as PCSK9 inhibitors

is now transforming cholesterol management.

How PCSK9 Inhibitors Work

These medicines help the liver remove LDL cholesterol more efficiently. They block a protein (PCSK9) responsible for reducing the liver’s ability to clear LDL from the bloodstream. By suppressing this protein, the liver can maintain healthier cholesterol levels.

Key PCSK9 Treatments Available in India

Evolocumab (Repatha):

Marketed in India by Dr. Reddy’s Laboratories under license from Amgen, this injection costs approximately ₹19,000–₹21,000 per dose. Since patients require two doses each month, the monthly cost can exceed ₹30,000.

Inclisiran (Leqvio):
A cutting-edge siRNA-based therapy from Novartis, sold under Indian brands like Sybrava, Crenzlo and Izirize. Unlike Evolocumab, Inclisiran prevents the PCSK9 protein from being produced in the first place.

Its biggest advantage: only two injections are needed per year. However, each shot is priced around ₹1.2 lakh.

With fewer doses and strong clinical results, Inclisiran is quickly emerging as a powerful alternative for people who struggle with persistently high cholesterol.

2. Fatty Liver Disease (MASLD/MASH): First-Ever Approved Treatment Changes the Outlook

Fatty liver disease — now widely termed MASLD

and its severe form MASH — has become one of the most widespread chronic health issues in India. Until recently, there was no specific medication to reverse liver damage caused by this condition.

New Breakthrough: Resmetirom (Rezdiffra)

A historic milestone came in 2024–2025 when the US FDA approved Resmetirom, the first medication proven to treat liver fibrosis (scarring) caused by MASH.

This once-daily pill acts by targeting thyroid hormone receptors in the liver, helping reduce fat accumulation, repair scarring and even lower LDL cholesterol.

While the drug is not yet available in India, several Indian pharma companies — including Morepen, Dr. Reddy’s and Mankind — are preparing to introduce it in 2026 once the main patent expires.

Other Effective Options

GLP-1 medications such as Semaglutide (Novo Nordisk) and Tirzepatide (Eli Lilly), originally designed for diabetes and weight loss, have also shown significant effectiveness in reducing liver fat.

In addition, Zydus Lifesciences offers Saroglitazar (Lipaglyn)

, an affordable treatment for NASH that costs around ₹1,500–₹2,000 per month.

3. Chronic Kidney Disease (CKD): Modern Therapies Reduce Progression

Chronic kidney disease is often called a “silent killer” because it develops gradually, mainly due to uncontrolled diabetes and hypertension.

SGLT2 Inhibitors

Medicines like Dapagliflozin (Forxiga) by AstraZeneca and Empagliflozin (Jardiance)

by Boehringer Ingelheim have significantly changed CKD management. These drugs reduce pressure on the kidneys and slow long-term damage.
Original brands cost ₹1,400–₹1,600 per month, but Indian generics are available for just ₹150–₹300.

Finerenone: A New Kidney-Protective Solution

Bayer’s Finerenone, a non-steroidal MRA, blocks mineralocorticoid receptors that trigger inflammation and fibrosis in kidney tissues. It is available at a monthly cost of ₹1,400–₹1,800.

Important Note

All treatments mentioned above require medical supervision. These are prescription-based medicines

, and patients should follow the guidance of qualified specialists before beginning any therapy